2024-06-01 05:30:37 ET
Summary
- Ocular Therapeutix has provided promising updates on its clinical trials for Axpaxli and Paxtrava, utilizing its Elutyx drug-eluting platform.
- The company has appointed a new CEO and raised funds, extending its cash runway until 2028.
- Ocular's pipeline includes treatments for wet-AMD, diabetic retinopathy, glaucoma, and other eye conditions, with potential for significant revenue growth.
Thesis
This article will be delving into the most recent pipeline, operational and financial updates from Ocular Therapeutix Inc. ( OCUL ).
Taking into account the potential progress of Axpaxli and Paxtrava as well as further potential uses of Elutyx as drug-eluting biodegradable devices, I think Ocular is worthy of consideration. Moreover, I believe the long cash-runway, which may allow Ocular to progress with the development of its leading product candidates, together with the leadership change are likely to support the company growth....
Read the full article on Seeking Alpha
For further details see:
Ocular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 Results